Rachel S.

Rachel S. has extensive experience in the pharmaceutical industry, notably serving as Director of Strategic Initiatives and Planning and Director of Launch Operations and Commercial Excellence at Novo Nordisk from March 2022 to February 2023, focusing on global launch plans for rare disease programs. Prior to this, Rachel held several key roles at Dicerna Pharmaceuticals, Inc., including Director of Business Development and Director of Commercial Excellence, contributing to partnership negotiations and developing launch excellence frameworks. Experience also includes working at Merck as an RNAi Medicinal Chemist and Medicinal Chemist from May 2009 to December 2013. Rachel holds an MBA in Health Sector Management from the Questrom School of Business at Boston University and a B.S. in Chemistry from Temple University, where academic achievements included the Dean’s List and a scholarship award.